Bryan Forrest

The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1<i>R</i>,2<i>S</i>)-2-(3-((<i>E</i>)-4-(((<i>cis</i>)-2,6-Dimethylmorpholino)methyl)styryl)-1<i>H</i>-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent

Peter B. Sampson, Yong Liu, Bryan Forrest et al. · Journal of Medicinal Chemistry · 2014 · 166 citations · Full text

The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3′[3<i>H</i>]indol]-2′(1′<i>H</i>)-ones as Orally Bioavailable Antitumor Agents

Peter B. Sampson, Yong Liu, Narendra Kumar Patel et al. · Journal of Medicinal Chemistry · 2014 · 109 citations

Pharmaceutical Science, Polo-like Kinase Family, Compound 18 +22

The Discovery of PLK4 Inhibitors: (<i>E</i>)-3-((1<i>H</i>-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents

Radoslaw S. Laufer, Bryan Forrest, Sze-Wan Li et al. · Journal of Medicinal Chemistry · 2013 · 71 citations · Full text

Molecular Biology, Pharmacotherapy, Chemical Biology +18

The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1<i>H</i>-indazole-5-carboxamides as Anticancer Agents

Yong Liu, Yunhui Lang, Narendra Kumar Patel et al. · Journal of Medicinal Chemistry · 2015 · 50 citations · Full text

Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3′-indolin]-2′-ones as potent PLK4 inhibitors with oral antitumor efficacy

Sze-Wan Li, Yong Liu, Peter B. Sampson et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 30 citations · Full text